Tecentriq® (atezolizumab) – Expanded indication
April 17, 2017 – Genentech announced the FDA approval of Tecentriq (atezolizumab) injection, to expand its use to patients with locally advanced or metastatic urothelial carcinoma (UC) who are not eligible for cisplatin chemotherapy.
Download PDF
